Published

Mounjaro leads to significantly more weight loss than Ozempic, study suggests

Summary by The Billings Gazette
The U.S. Food and Drug Administration has approved versions of tirzepatide and semaglutide to treat both type 2 diabetes and obesity.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 82% of the sources are Center
82% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)